Dr. Daniel Shahrooz Behroozan, MD

Dr. Behroozan practices at Dermatology Institute of Southern California in Santa Monica, California.

Dr. Behroozan's NPI, 1851325716, was assigned on July 10, 2006. Dr. Behroozan graduated from David Geffen School of Medicine at UCLA in 2000. Dr. Behroozan holds California license A76756.

Dr. Behroozan's primary practice is Dermatology Institute of Southern California, at 2207 Lincoln Blvd, Santa Monica, CA 90405 in Los Angeles County. The practice phone is (310) 392-1111.

Dr. Behroozan's primary practice is Dermatology Institute of Southern California in Santa Monica, California. The medical group on file is Dermatology Institute of Southern California. Dmand AI also links Dr. Behroozan to 1 more group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Behroozan practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Behroozan's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Behroozan is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Behroozan's licenses on file in 2 states: California and Texas.

Dmand AI lists acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, itchy rashes, rash and scalp rash among the conditions Dr. Behroozan treats.

CMS data shows 2,613 Medicare services from Dr. Behroozan across 29 procedure codes in 2024, for 508 Medicare patients. Medicare paid $405,774 for them. Every service was in an office.

CMS counts 508 Medicare patients who saw Dr. Behroozan in 2024. The largest group is 65 to 74, with 226 patients. 75% of them have high cholesterol, and 61% have high blood pressure. Their average risk score is 1.01, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Behroozan's median patient age at 49, with 49% women.

In 2024, Dr. Behroozan wrote 259 Medicare Part D claims for 170 patients. 98% of them were for generic drugs. CMS names the drug for 191 of them, across 7 drugs with 11 or more claims each, at $1,867 in total drug cost. In 2023, CMS named 184 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Behroozan for performance year 2024, reported as part of a group. Dr. Behroozan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 127 procedures of melanoma (skin cancer) excision by Dr. Behroozan, more than 95% of the clinicians it reports for that procedure.

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 20 papers to Dr. Behroozan, published from 2009 to 2012. The most frequent topics are Carcinoma, Basal Cell, Mohs Surgery and Skin Neoplasms. Dr. Behroozan has published most often in Dermatol Surg. Dr. Behroozan's most frequent co-authors are Adrienne Shoss Glaich, MD, Navid Ezra, MD and Paul M. Friedman, MD.

CMS Open Payments shows 1,098 general payments to Dr. Behroozan from 51 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 74% of the total. Galderma Laboratories, L.P. paid the most, $123,339.

Dr. Behroozan graduated from David Geffen School of Medicine at UCLA in 2000.

Dr. Behroozan is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.